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The commentary by Chiou (this issue) raised several questions and offered 
alternative points of view on the interpretation and limitations of the perme- 
ability concept in the biopharmaceutical discipline. We briefly review the 
approaches below and show that the calculated clearance per unit area and 
permeability are identical variables and the central point in such analysis is 
the choice of luminal reference drug concentrations. We further consider the 
effective permeability view as most appropriate because it provides a sound 
intuitive understanding of the physical and mechanistic principles underlying 
the transport process. 
The starting point for analyzing drug transport across the membrane 
wall of a tube is the relationship between the mass entering and leaving the 
tube 
dM/dt= Qi, Cin - OoutCout = Q ( C i n  - -  Cout) (1) 
where Ca, and Cout are the inlet and outlet drug concentrations, respectively, 
and Q is the flow through the tube, usually assumed to be constant. The 
mass balance relationship can then be set to describe the transport rate of 
the drug across the tube membrane (absorbed mass) according to Fick's 
first law 
d M / d t = A .  P ~C lump" C bl~176 efrt re~ - =f ) (2) 
where A is the surface area of the membrane, Pefr is an effective permeability 
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Fig. 1. Illustration of the different transport barriers a drug molecule has to pass during the 
intestinal absorption process (UWL: unstirred water layer, ECF: extracellular fluid, Pm: mem- 
brane permeability). 
coefficient and the reference concentrations are on the two opposite sides of 
,.~lume, CblOod (Fig. 1). It is usually assumed that the the intestinal mucosa; ,--rof , rof 
/ cblood~ reference blood concentration ~ ref ) is negligible in comparison with the 
lumen concentration. This has been directly shown to be valid for antipyrine 
in humans (1). 
Alternatively, the approach of using a clearance concept is described 
by 
d M / d t  = ClabsC'r~ 'r (3) 
where Clabs is the absorptive clearance (ml/min) into the body and Cref is 
the same reference concentration as used above. Using the same assumption 
for Eqs. (2) and (3), it is clear that Pert is equal to Clabs/A, if the same 
reference concentration is used. Thus, the use of the term "effective perme- 
ability" or "absorptive clearance per unit area" is perhaps a matter of prefer- 
ence. However, we prefer the permeability view since it is based on 
Permeability and Clearance Views of Drug Absorption 335 
fundamental mass transport principles, e.g., Fick's first law applied to a 
membrane and models for drug transport based on permeabilities have been 
extensively developed (2). An additional difficulty in using absorptive dear- 
ance itself is that it depends on surface area and as a result the clearance 
would depend on the length of the segment studied and would make com- 
parisons between experiments and laboratories with slightly different tech- 
niques much more uncertain. Moreover, while clearance has had a wide 
application in general, it is most often used to describe drug elimination in 
pharmacokinetics. It has the unit of ml/min and is often expressed as the 
virtual volume of fluid from which the substance is completely removed per 
unit time (3). The physical understanding of Clabs is therefore not as direct 
as for Pcff in the more defined intestinal perfusion system. 
The calculation of permeability or clearance per unit area each requires 
an estimation of membrane surface area [,4, Eqs. (1) and (2)]. This has 
conventionally been taken to be the geometrical surface area based on the 
length and radius of the perfused segment. The normal intestine is, of course, 
not straight or rigid, this implies that the actual absorbing surface area effect 
is incorporated into the measured effective permeability. The "true" cellular 
membrane permeability (Pro) of the intestinal mucosa undoubtedly varies 
from villus crypt to tip and axially from stomach to colon. The effective 
permeability (Pc~) will be an average over the segment perfused. 
The need for a reference concentration is evident with either definition, 
and the available choices are the inlet, outlet, or some calculated average 
concentration. The choice is usually made based on which concentration 
more closely approximates the concentration adjacent to the intestinal wall 
(Cw). Ideally, one would have the concentration at each point along the 
absorbing surface, since Fick's law is a local law, which would provide 
us with "local" permeabilities. For some experimental systems where the 
hydrodynamics are well defined, the transport equations for the convective 
process and diffusion can be solved analytically (2,4). However, the regional 
perfusion approach in the human intestine only offers entering and leaving 
drug concentrations. For this system we have determined, based on non- 
steady-state analysis of tracer curves, that the hydrodynamics is described 
best by a mixing-tank model, for convection within a perfused 10-em long 
jejunal segment (4,5). 
The effective permeability includes the process of transport to the mem- 
brane (aqueous permeation, e.g., diffusion and convection to the membrane), 
cell mucosa permeation including mucin and membrane translocation pro- 
cesses (passive and/or active transcellular transport or passive paracellular 
diffusion/convection), and perhaps transport through the cytosol, basolat- 
eral membrane, interstitial fluid, and capillary wall to the blood (see Fig. 1) 
(6-8). However, it is assumed that the permeability is dominated by the 
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largest resistance which is usually considered to be the apical brush border 
membrane. Drug metabolism in the cell cytosol may influence the measured 
permeability through further maintaining sink conditions intracellularly, and 
carrier-mediated exsorption of a drug will give a "lower" effective perme- 
ability. These processes certainly need to be accounted for in any detailed 
model of the drug transport mechanism across the mucosal membrane. 
Furthermore, the permeability is measured at steady state in the perfusion 
system so that the binding process that may influence (non-steady-state) 
drug permeation are quasi-steady state and do not contribute to the 
measured permeability (6). The human effective permeability has also been 
shown to correlate very well with the fraction absorbed in vivo for a broad 
range of structurally different compounds, which also supports the mass 
balance between disappearance and appearance rate (9,10, Lennern/is et al., 
to be published). In addition, we have compared human Pe~ values between 
the Caco-2 model and the rat perfusion model considering P~fr, and the 
usefulness of the permeability concept was evident (11,12). Finally, drug 
instability in the intestinal lumen and/or brush border metabolism also 
influences the observed permeability but can be approximated by analyses 
of the metabolites in the perfusate and as well in vitro studies. However, 
these considerations apply to both permeability and clearance views. 
In summary, the permeability view of the absorption process is the most 
fundamentally sound view upon which to base analysis of this complex 
process. The commentary by Chiou advancing the absorption clearance con- 
cept, while correctly noting many of these complexities, does not offer any 
real advance in analysis or understanding and may well add to the confusion 
in this field. 
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